| Literature DB >> 29605184 |
Stéphane Chevrier1, Helena L Crowell2, Vito R T Zanotelli3, Stefanie Engler1, Mark D Robinson4, Bernd Bodenmiller5.
Abstract
The advent of mass cytometry increased the number of parameters measured at the single-cell level while decreasing the extent of crosstalk between channels relative to dye-based flow cytometry. Although reduced, spillover still exists in mass cytometry data, and minimizing its effect requires considerable expert knowledge and substantial experimental effort. Here, we describe a novel bead-based compensation workflow and R-based software that estimates and corrects for interference between channels. We performed an in-depth characterization of the spillover properties in mass cytometry, including limitations defined by the linear range of the mass cytometer and the reproducibility of the spillover over time and across machines. We demonstrated the utility of our method in suspension and imaging mass cytometry. To conclude, our approach greatly simplifies the development of new antibody panels, increases flexibility for antibody-metal pairing, opens the way to using less pure isotopes, and improves overall data quality, thereby reducing the risk of reporting cell phenotype artifacts.Entities:
Keywords: CyTOF; channel interference; compensation; imaging mass cytometry; mass cytometry; signal crosstalk; spillover
Mesh:
Substances:
Year: 2018 PMID: 29605184 PMCID: PMC5981006 DOI: 10.1016/j.cels.2018.02.010
Source DB: PubMed Journal: Cell Syst ISSN: 2405-4712 Impact factor: 10.304
Figure 1Properties of Mass Cytometry Spillover and Description of a Single-Stained Bead-Based Compensation Workflow
(A) Schematic view of sources of signal interference that affect mass cytometry.
(B) Histogram showing signal intensity upon staining of PBMCs with the indicated concentrations of anti-CD44 antibody.
(C) The panels on the left display, as scatterplots, the median intensities of signals obtained in the main channel (143Nd) and spillover-affected channels for PBMCs stained with anti-CD44 antibody. Linear models are shown as blue lines. For each relationship, the coefficient of determination is indicated. The panels on the right display the spillover percentage calculated for each concentration. The blue lines indicate the spillover as assessed based on the highest antibody concentration.
(D) Scatterplots showing the signals of the anti-CD44 antibody in the main channel and in the spillover-affected channels before compensation (left column), after compensation with the conventional fluorescent flow cytometry approach (middle column), and after compensation with the NNLS method (right column). The green box shows how the NNLS compensation better preserves the data structure of a channel unaffected by spillover (blue box) than standard flow cytometry compensation does (orange box).
(E) Depiction of the workflow used to correct for spillover. Staining of control antibody-capture beads and samples are performed in parallel. Single-stained beads are pooled, and mass cytometry data are acquired on the beads and the samples. The CATALYST R package enables identification of the single-positive bead populations, calculates the compensation matrix, and applies the matrix to correction of sample data for spillover.
Figure 2Spillover Estimation and Current Limitations of Compensation due to Saturation Effects
(A) Spillover matrix calculated based on single-stained beads. Values on the diagonals are 1. By default, spillover is calculated only in potentially affected channels, which include M±1, those corresponding to known isotopic impurities, and M+16 (Figure S2D). Numbers in the cells indicate percentages of spillover by channels in rows into channels in columns. Numbers in the last column show the total amount of signal received in the corresponding channels.
(B) Scatterplots showing signal due to anti-HLA-ABC labeled with 172Yb and anti-CD3 labeled with 173Yb from pooled single-stained beads and multiplexed-stained PBMCs before and after compensation with standard flow cytometry methods (middle) and NNLS (bottom).
(C) Dot plots showing the median counts in each channel potentially affected by spillover for uncompensated data, compensated data, and NNLS-compensated data obtained upon analyses of single-stained beads and multiplexed-stained PBMCs. For multiplexed-staining, cells were stained with two panels where half of the channels were left empty, see (Table S1) to enable spillover assessment in absence of staining. For each dataset, the average sum of squares is shown on top of the graph.
(D) Dot plots showing the spillover in percent for the indicated relationships assessed on cells stained with increasing amount of barcoding reagents and identical antibody concentration. A linear model was fit to each relationship (blue lines), and the slope is indicated above each plot.
(E) Dot plots showing the spillover in absolute counts for the indicated relationships assessed on cells stained with increasing amount of barcoding reagents and identical antibody concentration.
(F) Scatter plot showing the relationship between the original signal and the most affected spillover channel for the indicated antibody-metal pairs on a linear scale. The dotted line and the red line show how the linear relationship is lost above 5,000 dual counts.
Figure 3Correction of Spillover Artifacts in Mass Cytometry Data Using Compensation
(A) t-SNE map displaying data on a subset of 20,000 PBMCs analyzed with our 36-antibody panel and colored by marker expression for three pairs of antibodies labeled with two different metal isotopes before (left) and after (right) spillover correction based on NNLS compensation. The percentages of spillover affecting each channel in the uncompensated dataset are indicated.
(B) Scatterplots showing the relationships between the channels displayed in (A) and the channels responsible for most of the spillover before and after compensation. The same relationship is shown for the same antibody in channels not affected by spillover.
(C) Heatmaps showing the expression of the indicated markers in the different clusters before compensation (upper panel) and after NNLS compensation (lower panel). Dashed boxes highlight regions in the plot that changed upon compensation.
(D) Plots showing the frequency of significant correlations (Spearman, p < 0.005) between markers for each cluster containing more than 200 cells. Frequency was set to 1 for the uncompensated values.
(E) Correlation heatmap across all markers for cluster 12 before (upper panel) and after NNLS compensation (lower panel). The clustering is based on uncompensated data.
Figure 4Spillover Affects IMC Data and Can Be Corrected Using Our Compensation Strategy
(A) Binning the signals of an imaged 166Er metal spot (to the 95th percentile of the 166Er pixel values) into 20 bins with equal pixel numbers shows a linear relationship between 166Er and 167Er over several orders of magnitude (upper panel). The relationship between 166Er and 168Er appears linear but saturates at the higher counts (lower panel).
(B) Representative image section of a breast cancer tissue sample imaged by IMC. Top row shows uncompensated images of 166Er (used to label antibody to carbonic anhydrase), 167Er (no antibody labeled with this metal), and 168Er (used to label anti-KI67). The bottom row shows corresponding NNLS compensated images. For visualization, a 3 × 3 pixel median filter was used to reduce noise. Scale bars, 20 μm. Red arrows indicate part of the image where low signal was removed by compensation.
(C) Segmentation mask shown on representative images described in (B). The mean pixel intensities of the signals observed in the indicated channels per cell are displayed.
(D) Scatterplots from single-cell segmentation data from the IMC images before (left) and after (right) compensation. Arcsinh transformed ion counts (cofactor of 2) are shown.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| CD8a (RPA-T8) – purified | Biolegend | Cat# 301002; RRID: |
| CD64 (10.1) – purified | Biolegend | Cat# 305002; RRID: |
| CD23 (EBVCS-5) – purified | Biolegend | Cat# 338502; RRID: |
| CD68 (Y1/82A) – purified | Biolegend | Cat# 333802; RRID: |
| CD36 (5-271) – purified | Biolegend | Cat# 336215; RRID: |
| CD4 (RPA-T4) – purified | Biolegend | Cat# 300502; RRID: |
| CD20 (H1(FB1)) – purified | Becton Dickinson | Cat# 555677; RRID: |
| CD68 (KP1) – purified | Biolegend | Cat# 916104; RRID: |
| CD20 (L26) – purified | eBioscience | Cat# 14-0202-82; RRID: |
| CD123 (6H6) – purified | Biolegend | Cat# 306002; RRID: |
| CD11b (M1/70) – purified | Biolegend | Cat# 101202; RRID: |
| CD99 (HCD99) – purified | Biolegend | Cat# 318002; RRID: |
| CD273/PD-L2 (MIH18) – purified | Biolegend | Cat# 345502; RRID: |
| CXCR4 (12G5) – purified | Biolegend | Cat# 306502; RRID: |
| CD7 (M-T701) – purified | Becton Dickinson | Cat# 555359; RRID: |
| CD32 (FUN-2) – purified | Biolegend | Cat# 303202; RRID: |
| CD16 (3G8) – purified | Biolegend | Cat# 302002; RRID: |
| CD14 (RMO52) – purified | Beckman Coulter | Cat# A22331; RRID: |
| HLA-ABC (W6/32) – purified | Biolegend | Cat# 311402; RRID: |
| HLA-DR (L243) – purified | Biolegend | Cat# 307602; RRID: |
| CD15 (HI98) – purified | Biolegend | Cat# 301902; RRID: |
| CD3 (UCHT1) – purified | Biolegend | Cat# 300402; RRID: |
| CD45 (HI30) – purified | Biolegend | Cat# 304002; RRID: |
| CD8b (SIDI8BEE) - purified | eBioscience | Cat# 14-5273; RRID: |
| CD22 (HIB22) - purified | Biolegend | Cat# 302502; RRID: |
| CD66a/c/e (ASL-32) | Biolegend | Cat# 342302; RRID: |
| CD192 (K036C2) | Biolegend | Cat# 357202; RRID: |
| CD93 (R139) | eBioscience | Cat# 14-0939-82; RRID: |
| carbonic anhydrase IX (polyclonal) | R&D Systems | Cat# AF2188; RRID: |
| KI67 (8D5) | CST | Cat# 9449BF; RRID: |
| Buffy Coat | Zurich Blood Transfusion Service | N/A |
| Breast cancer tissue sections | University Hospital Zurich - Archives of the Institute of Surgical Pathology | N/A |
| Paraformaldehyde | Electron Microscopy Sciences | Cat# 15710 |
| Bromoacetamidobenzyl-EDTA (BABE) | Dojindo Laboratories | Cat# B437-10 |
| Maleimido mono amide DOTA (mDOTA) | Macrocyclics | Cat# B-272 |
| Iridium | Fluidigm | Cat# 201192A |
| Maxpar X8 Multimetal labeling kit | Fluidigm | Cat# 201300 |
| Lanthanide (III) metal isotopes as chloride salts | Fluidigm | N/A |
| FcR Blocking Reagent, human | Miltenyi Biotech | Cat# 130-059-901 |
| Mass cytometry data | This paper | |
| Imaging mass cytometry data | This paper | |
| FlowJo v10.0.7 | N/A | |
| Cytobank | ||
| Concatenation tool | Cytobank, Inc | |
| Normalizer | ||
| Single cell debarcoder | ||
| t-SNE | ||
| PhenoGraph | ||
| CATALYST | This paper | |
| Python 3.4.3 | Python Software | |
| Ilastik 1.1.19 | ||
| R 3.3.2 | R Core Team, 2016 | |
| CellProfiler | ||